AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders, has announced the appointment of Dr. Phillipe Prokocimer as new Chief Medical Officer. Dr. Prokocimer brings more than 30 years of experience within antimicrobial drug development and has been involved in successful FDA approval of 6 New Drug Applications including 5 antibacterial compounds: Doripenem (Doribax®), Quinupristin/dalfopristin (Synercid®), Sparfloxacin (Zagam®), Clarithromycin (Biaxin®) and Tedizolid Phosphate (Sivextros®). Dr. Prokocimer will join as a full-time Chief Medical Officer for AntibioTx and lead the clinical development team.

The CEO of AntibioTx, Rasmus Toft-Kehler, commented: “Dr. Prokocimer’s experience and track record in clinical development is exceptional and of significant importance to AntibioTx”, and further added; ”Dr. Prokocimer joins the company at an exciting time and will be playing a key role in the design and execution of upcoming Phase II trials”.

Dr. Prokocimer has been the Chief Medical Officer of Trius Therapeutics from 2007 until its acquisition by Cubist in 2014. Here he was appointed Senior Vice President of Clinical Development at Cubist until it was acquired by Merck in 2015. At Merck, he kept a position as Senior Vice President of Clinical Development as Head of the San Diego site. Dr. Prokocimer received his medical degree from the School of Medicine in Paris, France and a Post-Doctoral Research Fellowship from Stanford University.

The appointment of Dr. Prokocimer is well aligned with the company’s strategy to expand its US presence. AntibioTx recently established a US subsidiary and seeks to build a clinical development team with a basis in San Diego, California.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.